TheraRadar
Data updated: May 26, 2026

Kedrab (rabies immune globulin (human))

Approved 2017-08-22
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2017-08-22
Routes
Subcutaneous
Dosage Forms
Solution

Companies

Active Ingredient: Rabies Immune Globulin (Human)

Kedrab Approval History

2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2017 to 2017
Aug 2017 ORIGINAL
Update · CBER biologic (Purple Book)

What Kedrab Treats

1 FDA approvals

Originally approved for its first indication in 2017 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03965962 results posted VRV13 2018-004055-20, U1111-1216-6151 Ph 3 completed Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Kedrab FDA Label Details

Track Kedrab with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.